 |
| Professor Geoffrey Cloud |
Research Manager, Department of Neuroscience, Central Clinical School
An opinion piece published in the journal Stroke proposes the re-purposing of a potent existing drug, tranexamic acid (TXA), for the treatment of cerebral amyloid angiopathy (CAA), a devastating cause of stroke due to intracerebral haemorrhage and dementia.
Professor Geoffrey Cloud, Director of Stroke Services, Alfred Health and Group leader, Department of Neuroscience at the Central Clinical School, said,
‘Cerebral amyloid angiopathy (CAA) is a neurological condition that is increasingly being diagnosed in clinical practice, but sadly there is no specific treatment for patients.’
